Core Insights - SenseTime has completed the spin-off of its AI medical business, establishing SenseTime Medical, which has raised 1 billion yuan in funding within six months, positioning itself as a near-unicorn in the industry [2] - The core objective of SenseTime Medical is to construct a "world model" in the medical field, driven by a medical large model, aiming to design and empower the "future hospital" [2] - The company employs a "dual middle platform" strategy to ensure efficient collaboration between its core model and multimodal models, facilitating zero-code application development [4] Technology and Model Development - SenseTime Medical's core model, "Da Yi®," excels in processing medical long texts, knowledge Q&A, and complex reasoning, outperforming general models like DeepSeek and GPT-5 in eight professional testing dimensions [2] - The model's advantages stem from three technological supports: a high-quality corpus covering over 100 medical disciplines and approximately 400 billion Chinese characters, an industrial-grade RAG framework for evidence tracing, and specialized training to enhance clinical reasoning [2] Commercialization and Partnerships - SenseTime Medical has launched over 40 AI modules in clinical settings, covering various clinical directions, with its smart pathology system improving departmental efficiency by 30%-50% and achieving nearly 100% sensitivity in tumor detection [6] - Collaborations include partnerships with Tsinghua Changgung Hospital for liver decision-making AI and Roche for a research platform covering 700 top-tier hospitals across 90 cities [7] - The company has also established a medical big data training facility with Shanghai Shenkang Hospital Development Center and deployed smart diagnostic platforms in hospitals [7] International Expansion - SenseTime Medical has accelerated its overseas expansion, obtaining Singapore's first AI chest CT diagnostic device registration and securing its first business in Indonesia, targeting markets in Southeast Asia and the Middle East [7] Team and Future Vision - The current team consists of approximately 100 members, with over 70% in research and development, featuring talents from top universities and leading tech companies [7] - The CEO, Zhang Shaoting, envisions transitioning AI from "text Q&A" to "dynamic simulation," aiming to create a "digital laboratory" that replicates human physiological processes and predicts treatment outcomes [7]